European Journal of Cardiovascular Medicine

Background: STEMI is a significant cause of morbidity and mortality in patients with CAD. All STEMI patients should undergo risk stratification at the earliest as these patients are at highest risk for developing complications. TIMI risk score is used to predict both early and one year mortality. MHR has emerged a prognostic marker and has been related to cardiovascular outcomes in various CVDs. Methods: 103 acute STEMI cases admitted to KIMS Hospital, Hubballi meeting the inclusion criteria were considered in 2year time period. Of these, 75 patients with a diagnosis of STEMI who underwent PCI with significant CAG findings were selected as the STEMI group and the remaining 28 patients, who had normal coronary arteries, were selected as the control group. The STEMI patients were then divided into two subgroups based on TIMI scores. Results: Among 103 study participants ,75.73 % were males and 24.27 % were females Mean age of STEMI group is 60.8 years.DM was found in 26.21 % and HTN was found in 45.63 % of participants. Mean HDL of the STEMI group is 41.6 mg/dl. Mean monocyte count of the STEMI group is 0.9 ×103 /µL. Mean MHR of STEMI group is 3 and mean TIMI score of STEMI group is 3.3. MHR is significantly higher in STEMI group. Conclusion: In this study it has been observed that MHR is associated with TIMI score in patients with STEMI. MHR can be used as a novel prognostic marker for risk stratification and may be as an predictor of future cardiovascular events in STEMI patients.